Michael Makris: Romiplostim Use Allows More Chemotherapy to Be Delivered on Time
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn about a recent article by Hanny Al-Samkari et al, published in The New England Journal of Medicine:
“Romiplostim use allows more chemotherapy to be delivered on time.
A paper in this week’s New England Journal of Medicine by Hanny Al-Samkari and colleagues reports on a double-blind study of Romiplostim vs Placebo for Chemotherapy-induced Thrombocytopenia.
84% of the Romiplostim and 36% of the Placebo group had no chemotherapy dose modifications.
All the patients had solid tumours.
We do not know if administering more chemo results in a survival advantage, since this would have required a larger trial and much longer follow-up.”
Title: Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
Authors: Hanny Al‑Samkari, César Muñoz, Çağlayan Geredeli, Ippokratis Korantzis, Beatriz González Astorga, Cagatay Arslan, Johnny Francisco Cordeiro Camargo, Florian Scotté, Giuliano Borges, Kejia Wang, Melissa Eisen, David J. Kuter, Gerald A. Soff
Read the Full Article on The New England Journal of Medicine
Other articles featuring Michael Makris on Hemostasis Today.
-
Mar 14, 2026, 15:45Nicole Odofin: The First Blood Drive Event at Channel 4
-
Mar 14, 2026, 15:40Jecko Thachil: Anticoagulation in Patients With Metabolic-Associated Fatty Liver Disease
-
Mar 14, 2026, 15:37Lorenz Räber: New Insights Into Silent Plaque Ruptures in AMI Patients
-
Mar 14, 2026, 15:11Abdul Mannan: Why Apixaban May Be the Safer Choice for Acute VTE
-
Mar 14, 2026, 15:09Cedric Hermans: New Viewpoint on the Challenges of Coagulation Rebalancing in Hemophilia
-
Mar 14, 2026, 15:07Soroush Sohrabi: Foam or Liquid for Spider Veins?
-
Mar 14, 2026, 14:59Donate Blood and Be the Reason Someone Survives – Damu Sasa
-
Mar 14, 2026, 14:45Abdulrahman Nasiri: Most Important Concepts and the Clinical Shift the COBRRA Trial Brings to Practice
-
Mar 14, 2026, 13:44Isabelle Mahé: Bleeding Risk Differs Across Solid Tumours in Cancer-Associated Thrombosis